Angiogenesis

ER-27319 is a potent and selective Spleen Tyrosine Kinase (SYK) inhibitor, known for its ability to suppress the tyrosine phosphorylation of SYK and thereby inhibit its enzymatic activity. This compound effectively blocks the release of antigen-induced allergic mediators from human and rat mast cells, exhibiting an IC50 of 10 μM. ER-27319 is a valuable tool for research in the field of allergic diseases, particularly in studies focused on mast cell activation and modulation.

Syk-IN-1 is a highly potent inhibitor of Syk (spleen tyrosine kinase), demonstrating an IC50 value of 35 nM. This compound effectively disrupts Syk-mediated signaling pathways, making it valuable for studies involving immune response, cell proliferation, and apoptosis. Syk-IN-1 is suitable for research applications focused on hematological malignancies and inflammatory diseases, facilitating the exploration of Syk's role in various biological processes.

(R,S)-MK-8457 is a dual inhibitor of SYK and ZAP70, key signaling molecules involved in immune cell activation. This compound exhibits potent inhibitory activity, making it a valuable tool for investigating the pathophysiology of autoimmune disorders. Its application in research focuses primarily on the study of rheumatoid arthritis and other inflammatory conditions.

Lanraplenib monosuccinate is a highly selective inhibitor of spleen tyrosine kinase (SYK), with an IC50 of 9.5 nM. This compound inhibits SYK activity in platelets through the glycoprotein VI (GPVI) receptor, making it a promising candidate for the treatment of inflammatory diseases. Notably, lanraplenib monosuccinate does not prolong bleeding time in preclinical models, indicating a favorable safety profile for potential therapeutic applications.

Syk-IN-8 is a selective Syk inhibitor that exhibits significant antiproliferative activity against various hematological tumor cell lines. By targeting and inhibiting the phosphorylation of PLCγ2, Syk-IN-8 serves as a valuable tool for investigating the molecular mechanisms underlying blood cancers and evaluating potential therapeutic strategies. Its specificity and efficacy make it an important reagent for researchers focused on hematological malignancies.

BI 894416 is a selective inhibitor of spleen tyrosine kinase (SYK), a key regulator involved in various immune responses. This compound is particularly relevant for studying the pathophysiology of severe asthma, making it valuable in the development of therapeutic strategies. Additionally, BI 894416 features a deuterium-labeled derivative, which serves as an internal standard in bioanalytical applications, enhancing the accuracy of quantitative assessments in research settings.

(rel)-PRT062607 is a selective inhibitor of Syk kinase, demonstrating high potency with an IC50 value of 1-2 nM. This compound exhibits over 80-fold selectivity against related kinases such as Fgr, Lyn, FAK, Pyk2, and Zap70. Its specificity makes it a valuable tool for studying Syk-mediated pathways in various biological contexts and offers potential applications in autoimmune and inflammatory disease research.

Syk-IN-7 is a selective inhibitor of spleen tyrosine kinase (SYK). It demonstrates significant inhibition of SYK activity, thereby impacting B-cell receptor signaling pathways and immune responses. This compound is valuable for studying the roles of SYK in immunological research and potential therapeutic applications in autoimmune diseases and lymphoid malignancies.

Syk-IN-2 is a selective inhibitor of spleen tyrosine kinase (Syk), a vital signaling molecule in various hematopoietic cells. Its inhibition modulates immune responses and has been implicated in the treatment of autoimmune diseases and certain cancers. This compound serves as a valuable tool for researchers investigating Syk-related pathways and potential therapeutic interventions.

NMS-0963 is a potent inhibitor of spleen tyrosine kinase (SYK), exhibiting an oral bioavailability and an IC50 value of 3 nM. This compound effectively inhibits the proliferation of BaF3-TEL/SYK cell lines at a concentration of 27 nM, making it a valuable tool for investigating SYK-related pathways in various biological contexts and potential therapeutic applications in diseases involving SYK dysregulation.

BI1002494 is a selective inhibitor of spleen tyrosine kinase (SYK) with oral bioavailability. It demonstrates potent inhibitory activity with an IC50 of 115 nM against high-affinity IgE receptor-mediated degranulation in mast cells and basophils. This compound is a valuable tool for studying immune responses and can be applied in a variety of immunology research applications.

Type-II-IN-1 is a potent type II inhibitor of spleen tyrosine kinase (Syk), exhibiting an IC50 value of 2.1 nM. It specifically interacts with the DFG-out conformation of Syk, making it a valuable tool for the study of immunological processes. This compound is particularly relevant for research applications related to asthma and other immune-related disorders.

Syk-IN-13 is a selective inhibitor of Spleen tyrosine kinase (Syk). It has demonstrated significant biological activity in modulating immune responses and inflammatory pathways, making it a valuable tool for researching conditions such as rheumatoid arthritis and systemic lupus erythematosus. This compound allows for the exploration of Syk's role in various cellular processes, highlighting its potential as a therapeutic target in autoimmune diseases.

Syk-IN-11 is a selective inhibitor of Spleen tyrosine kinase (Syk) with a reported IC50 of 13 nM. This compound demonstrates significant biological activity and has applications in the research of autoimmune disorders such as arthritis, as well as hematological malignancies like chronic lymphocytic leukemia. Its role in modulating Syk signaling pathways makes it a valuable tool for elucidating disease mechanisms and developing potential therapeutic strategies.

A 83-01 sodium is a selective inhibitor of the transforming growth factor-beta (TGF-β) type I receptors ALK4, ALK5, and ALK7. With IC50 values of 12 nM, 45 nM, and 7.5 nM, it effectively blocks transcriptional activity induced by these kinases. This compound is valuable for research applications focused on TGF-β signaling pathways and regulation of cellular processes such as proliferation, differentiation, and epithelial-mesenchymal transition.

M4K-2009 is a potent inhibitor of ALK2, exhibiting an IC50 value of 13 nM, and is capable of penetrating the blood-brain barrier. In addition to its primary activity against ALK2, M4K-2009 demonstrates efficacy against the hERG potassium channel. This compound is valuable for research in the areas of bone morphogenetic protein signaling and related therapeutic applications.

(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.

(Rac)-Dencichine, the racemic form of Dencichin, targets Hypoxia-Inducible Factor (HIF) by inhibiting HIF prolyl-hydroxylase-2 (PHD-2) activity. This non-protein amino acid, derived from Panax notoginseng, exhibits significant biological activity in promoting HIF stabilization under normoxic conditions. Its ability to modulate HIF pathways makes it valuable in research applications related to cancer biology, ischemia, and metabolic regulation.

TRI-611 is an orally active molecular glue degrader that targets the anaplastic lymphoma kinase (ALK). It forms a ternary complex with the substrate receptor CRBN, leading to polyubiquitination and subsequent degradation of ALK, including resistant fusion proteins. TRI-611 effectively inhibits ALK-mediated downstream signaling and exhibits anti-proliferative effects in ALK-positive cancer cells. Preclinical studies demonstrate its capability to induce regression of ALK-positive non-small cell lung cancer tumors, making it a valuable tool for research into TKI-refractory tumors and central nervous system metastases.

Cyclo[K(N3)larllt] is a cyclic peptide that specifically targets the epidermal growth factor receptor (EGFR) with a Kd value of 5.09 μM and demonstrates selectivity for related proteins HER2 and HER3. This compound exhibits no cytotoxicity and does not inhibit the growth of EGFR-overexpressing cancer cells. Cyclo[K(N3)larllt] is ideal for use as a ligand in EGFR-targeted fluorescent conjugates, facilitating the detection of tumors with elevated EGFR levels. Its applications extend to research focused on colorectal cancer and related pathologies.

Peptide HRH is a polypeptide that specifically targets vascular endothelial growth factor receptors (VEGFR). It effectively inhibits VEGF-stimulated endothelial cell proliferation, thereby disrupting angiogenesis. Additionally, Peptide HRH demonstrates efficacy in suppressing corneal neovascularization. This peptide is suitable for research applications focused on anti-angiogenesis and related studies.

VEGFR2-IN-84 is a potent VEGFR2 inhibitor that operates as a multi-targeted tyrosine kinase inhibitor utilizing a naphthalene ring scaffold. It exhibits sub-nanomolar affinity for VEGFR2 and effectively inhibits other kinases, including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 disrupts the phosphorylation of VEGFR2, leading to significant reduction in endothelial cell proliferation, migration, and tumor angiogenesis. This compound demonstrates broad antiproliferative activity against various solid tumors, such as liver, lung, and renal cancers, while exhibiting low toxicity to normal cells. VEGFR2-IN-84 is suitable for research applications focused on malignant tumors.

ZW-49 is a potent orally active pan-EGFR inhibitor, demonstrating IC50 values ranging from 0.03 to 1.5 nM. This compound selectively targets various EGFR mutations while sparing wild-type EGFR and other familial targets, effectively blocking the ATP-binding pocket and a conserved hydrophobic subpocket without causing steric conflicts with PACC mutation P loops. ZW-49 exhibits significant anti-proliferative activity by inhibiting cancer cell proliferation, inducing G0/G1 phase cell-cycle arrest, and promoting apoptosis, making it a valuable reagent for cancer research, particularly in non-small cell lung cancer models.

Rinumafusp alfa is a human monoclonal antibody that specifically inhibits the epidermal growth factor receptor (EGFR) by targeting ERBB3/HER3. This compound demonstrates potential in blocking tumor cell signaling pathways, thereby impeding tumor growth and progression. It is primarily utilized in research applications focused on cancer biology and therapeutic development targeting EGFR-related pathways.

FLT3-IN-40 is a type I ATP-competitive inhibitor of FLT3, demonstrating an IC50 of 16.26 nM. This compound effectively reduces FLT3 autophosphorylation and downregulates ERK phosphorylation, thereby exhibiting significant antiproliferative activity, influencing cell cycle regulation, and promoting apoptosis. FLT3-IN-40 is particularly valuable for research applications focused on acute myeloid leukemia.

TG 100948 is a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase Src. This compound demonstrates significant biological activity by reducing retinal edema and retinal thickening, as well as eliminating bullous edema cysts in rat models of ischemic retinal vein occlusion. TG 100948 is valuable for research into the pathophysiology and potential treatments of ischemic retinal vein occlusion.